Mifamurtide vs Pidotimod
Head-to-head comparison of Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) and Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mifamurtide | Pidotimod |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Muramyl Tripeptide Phosphatidylethanolamine | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid |
| Molecular Weight | N/A | 244.27 Da |
| Half-Life | 2-4 h | 3-4 h |
| Amino Acids | N/A | 2 |
| Typical Dose | 2 mg/m2 | 400-800 mg/day |
| Route | Intravenous | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 150 | 200 |
| Research Status | Clinical | Clinical |
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Research Overview
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.